OBJECTIVE: Our purpose was to assess upper urinary tract opacification and the performance of split-bolus MDCT urography for upper tract tumors in patients with hematuria. MATERIALS AND METHODS: Between January 2004 and December 2006, we identified 200 patients (119 men, 81 women; median age, 58 years, age range, 18-89 years) who underwent MDCT urography for hematuria. MDCT urography included unenhanced and combined nephrographic and excretory phase imaging of the urinary tract. Images were independently reviewed by two radiologists blinded to the final diagnosis. The degree of upper urinary tract opacification and the diagnosis were recorded. Prospective interpretations were also reviewed. The standard of reference included all available clinical, imaging, and laboratory data for up to 12 months after MDCT urography. Sensitivity, specificity, accuracy, and positive and negative predictive values were calculated for upper tract tumors for prospective and retrospective interpretations. RESULTS: For reviewers 1 and 2, 85.1% and 84.5% of segments were at least 50% opacified, respectively. Final diagnoses for hematuria were no cause, 123 (61.5%); urothelial cancer, 27 (13.5%); nonmalignant, 46 (23%) and indeterminate, four patients (2%). There were nine upper tract cancers. Sensitivity, specificity, and accuracy for upper tract cancers for prospective interpretation, reviewer 1 and reviewer 2, were 100%, 99%, 99%; 100%, 99.5%, 99.5%; and 88.9%, 99.0%, 98.5%, respectively. CONCLUSION: Split-bolus MDCT urography provided at least 50% opacification of the majority of upper urinary tract segments and had high sensitivity, specificity, and accuracy for the detection of upper urinary tract tumors.
OBJECTIVE: Our purpose was to assess upper urinary tract opacification and the performance of split-bolus MDCT urography for upper tract tumors in patients with hematuria. MATERIALS AND METHODS: Between January 2004 and December 2006, we identified 200 patients (119 men, 81 women; median age, 58 years, age range, 18-89 years) who underwent MDCT urography for hematuria. MDCT urography included unenhanced and combined nephrographic and excretory phase imaging of the urinary tract. Images were independently reviewed by two radiologists blinded to the final diagnosis. The degree of upper urinary tract opacification and the diagnosis were recorded. Prospective interpretations were also reviewed. The standard of reference included all available clinical, imaging, and laboratory data for up to 12 months after MDCT urography. Sensitivity, specificity, accuracy, and positive and negative predictive values were calculated for upper tract tumors for prospective and retrospective interpretations. RESULTS: For reviewers 1 and 2, 85.1% and 84.5% of segments were at least 50% opacified, respectively. Final diagnoses for hematuria were no cause, 123 (61.5%); urothelial cancer, 27 (13.5%); nonmalignant, 46 (23%) and indeterminate, four patients (2%). There were nine upper tract cancers. Sensitivity, specificity, and accuracy for upper tract cancers for prospective interpretation, reviewer 1 and reviewer 2, were 100%, 99%, 99%; 100%, 99.5%, 99.5%; and 88.9%, 99.0%, 98.5%, respectively. CONCLUSION: Split-bolus MDCT urography provided at least 50% opacification of the majority of upper urinary tract segments and had high sensitivity, specificity, and accuracy for the detection of upper urinary tract tumors.
Authors: Leon Will; Frederik L Giesel; Martin T Freitag; Anne K Berger; Walter Mier; Klaus Kopka; Stefan A Koerber; Hendrik Rathke; Christophe Kremer; Clemens Kratochwil; Hans-Ulrich Kauczor; Uwe Haberkorn; Tim F Weber Journal: Cancer Imaging Date: 2017-12-20 Impact factor: 3.909